|
Dear VIJAY PITHADIA: Your August 2014 digital issue of P&T journal is available. This issue contains: Feature articles - Letters to the Editor
- HEALTH CARE & LAW
Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees
Part 1: Deconstructing Dispensing Errors
A comprehensive analysis of malpractice claims experience from a professional liability insurer, Healthcare Providers Service Organization, can help P&T committees better understand the risks and challenges they encounter each day.
James O'Donnell, PharmD; and F. Randy Vogenberg, RPh, PhD
- Are Specialty Drug Prices Destroying Insurers And Hurting Consumers?
A Number of Efforts Are Under Way to Reduce Price Pressure Organizations are trying to address the high cost of "specialty" medications that treat conditions such as cancer, hepatitis C, and multiple sclerosis. While comprising less than 1% of U.S. prescriptions, these drugs now account for 27% of pharmacy spending.
Stephen Barlas
- Irritable Bowel Syndrome: Current And Emerging Treatment Options
Irritable bowel syndrome, a functional gastrointestinal disorder of uncertain pathophysiology, affects up to 55 million Americans. Medications available or in development include antispasmodics, antidepressants, and antidiarrheals.
Lauren Peyton, PharmD, CDE; and Joy Greene, PharmD
- MEETING HIGHLIGHTS
European Hematology Association
Attendees at the 19th Congress of the European Hematology Association in Milan, Italy, heard reports on new therapies for acute myeloid leukemia, chronic lymphocytic leukemia, -thalassemia, multiple myeloma, and polycythemia vera.
Walter Alexander
- PIPELINE PLUS
Ulcerative Colitis and Crohn's Disease
As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn's disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.
Kunj Gohil, PharmD, RPh; and Brielle Carramus
Plus our regular columns: Medication Errors, Prescription: Washington, New Drugs/Drug News/New Medical Devices, Pharmaceutical Approval Update, and Drug Forecast.
Click here to begin reading the current issue.
Click here to subscribe to P&T journal
Call for Papers
P&T is accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please contact Sonja Sherritze, via phone (267-685-2779) or mobile 267-907-5642) or e-mail (ssherritze@medimedia.com) for more information.
We hope you enjoy this issue of P&T. If you have any comments or questions about this digital format, please e-mail us at mail@ptcommunity.com. Sonja Sherritze Editor |
Posts
